| Description |
A significant number of patients with Hepatocellular Carcinoma (HCC) are not candidates for surgical resection. Radiofrequency ablation (RFA) is a new modality of treatment for unresectable HCC that has gained much enthusiasm in recent years. Ablation allows for the increased preservation of healthy liver tissue. While initial complete ablation rate is high, some patients develop local recurrence during follow-up. The addition of ThermoDox®, systemically delivered, heat-activated liposome encapsulated doxorubicin, to this ablation procedure has the potential to improve local control by the creation of high local concentrations of doxorubicin in the boundary of the ablation margin resulting in increased ablation volume and achieves better tumor cell kill in and around the tumor margin. The liposome encapsulation reduces systemic side effects of doxorubicin and Phase I trial showed that it was well-tolerated.
The main purpose of this study is to find out if ThermoDox® increases the effectiveness of RFA. |
